Can Anyone Take Semaglutide for Weight Loss?

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has shown remarkable results in clinical trials, helping patients lose an average of 15% of body weight over 68 weeks. However, eligibility for this medication depends on your individual health status, medical history, and specific risk factors. PlexusDx works with you to identify whether semaglutide injection is a safe and effective option for your weight loss goals.

Who Should Not Take Semaglutide for Weight Loss

Certain medical conditions make semaglutide unsafe or contraindicated. People with a personal or family history of medullary thyroid cancer should not use semaglutide, as animal studies raised concerns about thyroid C-cell tumors. Additionally, anyone with a history of pancreatitis or severe gallbladder disease may need to avoid this medication due to GLP-1 receptor activity in those tissues.

Individuals taking other diabetes medications, particularly other GLP-1 agonists or insulin, should discuss combination therapy carefully with their healthcare provider before starting semaglutide. Pregnancy and breastfeeding are also contraindications, since the medication has not been adequately studied in these populations. PlexusDx requires a comprehensive health screening to identify these risk factors before treatment begins.

Medical Eligibility Requirements for Semaglutide Therapy

Most adults with a BMI of 27 or higher and at least one weight-related health condition—such as high blood pressure, type 2 diabetes, or high cholesterol—meet the basic criteria for semaglutide consideration. Those with a BMI of 30 or above are also candidates regardless of other conditions. However, passing these thresholds does not guarantee approval; PlexusDx evaluates kidney function, liver function, and cardiovascular history to ensure safety.

A stable baseline health assessment is critical before starting semaglutide injection. This includes current blood pressure readings, fasting glucose levels if available, and a review of all current medications for potential interactions. Patients with uncontrolled hypertension, severe liver disease, or acute kidney injury may need to address these conditions first or may not be candidates at all.

How PlexusDx Assesses Your Suitability for Semaglutide

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Special Populations and Semaglutide Considerations

Older adults over 65 can often take semaglutide safely, but age-related changes in kidney function and medication sensitivity require careful dose adjustment and monitoring. Patients with well-controlled type 2 diabetes may be excellent candidates since semaglutide improves blood sugar control alongside weight loss, though their diabetes medications may need adjustment to avoid low blood sugar. People with a history of depression or anxiety should discuss mental health status, as GLP-1 use has been associated with mood changes in some individuals.

Individuals with a history of severe allergies or reactions to injectable medications should disclose this information during screening. Those taking blood pressure or heart medications should ensure their regimen is documented, as semaglutide's weight loss effects may eventually require dose adjustments in these medications. PlexusDx compounded semaglutide injection is available across all 50 states without insurance requirements, making it accessible for many populations, though individual eligibility still depends on the comprehensive health assessment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum age to take semaglutide from PlexusDx?

PlexusDx requires patients to be at least 18 years old. Younger adults should have a BMI of 27 or higher with a weight-related condition, or a BMI of 30 or above, to qualify for semaglutide injection therapy.

Can I take semaglutide if I have type 2 diabetes?

Yes, many people with type 2 diabetes are excellent candidates for semaglutide since it improves blood sugar control and promotes weight loss. However, existing diabetes medications may need to be adjusted to avoid low blood sugar episodes, and PlexusDx clinicians will coordinate this during your initial assessment.

How much does PlexusDx semaglutide injection cost?

Compounded semaglutide injection from PlexusDx is $189/mo month-to-month (or $149/mo on the 6-month plan) across all commitment tiers. Your dose may need to go up as you progress through treatment, but your price stays the same—PlexusDx does not charge more for higher doses.

What happens if I have a history of thyroid cancer?

A personal or family history of medullary thyroid cancer is a contraindication for semaglutide. If this applies to you, PlexusDx may recommend alternative treatments like tirzepatide injection or explore other personalized weight loss options based on your genetic profile.

How does the Precision Peptide Genetic Test help determine if semaglutide is right for me?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Semaglutide For Weight Loss 2
• Semaglutide Tablets For Weight Loss
• Semaglutide Pills For Weight Loss
• Oral Semaglutide Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.